What is OnKure?
OnKure is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapies for cancer and other serious diseases. The company's core strategy involves identifying new therapeutic targets and advancing personalized treatments that address the underlying biological mechanisms of diseases with high unmet medical needs. OnKure operates within the dynamic landscape of oncology and precision medicine, aiming to bridge the gap between scientific innovation and clinical application. Its focus is on delivering therapies that offer significant benefits where current treatment options are limited, all while adhering to stringent scientific evaluation and safety protocols.
How much funding has OnKure raised?
OnKure has raised a total of $266M across 4 funding rounds:
Series A
$7M
Series B
$55M
Series C
$54M
Stock/Share Issuance
$150M
Series A (2018): $7M with participation from Delian Capital
Series B (2021): $55M led by Perceptive Advisors, Cormorant Asset Management, Samsara BioCapital, BlackRock, Surveyor Capital, and Acorn Bioventures
Series C (2023): $54M supported by Surveyor Capital, Deep Track Capital, and Acorn Bioventures
Stock/Share Issuance (2026): $150M, investors not publicly disclosed
Key Investors in OnKure
Perceptive Advisors
Perceptive Advisors is an investment firm founded in 1999, specializing in funding innovative healthcare and life sciences technologies. They manage significant assets and are based in New York, NY.
Cormorant Asset Management
Cormorant Asset Management is a life sciences investment firm established in 2013, focusing on providing financial resources to promising companies in biotech and allied sectors, with a deep emphasis on scientific principles.
BlackRock
BlackRock is a global investment management firm headquartered in New York City, offering a wide range of investment products and services to institutional and individual investors across various asset classes.
What's next for OnKure?
The recent major strategic investment positions OnKure to accelerate its research and development pipeline, particularly in advancing its innovative therapies through clinical trials. This infusion of capital is expected to bolster the company's efforts in oncology and precision medicine, enabling further exploration of novel targets and the refinement of tailored treatment approaches. The company's commitment to addressing diseases with high unmet medical needs, coupled with its rigorous scientific standards, suggests a strategic focus on expanding its therapeutic portfolio and potentially forging key partnerships to enhance market reach and impact.
See full OnKure company page
